10 Frequently Asked Questions About Weight Loss Injections
GLP-1 receptor agonists—including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound)—have rapidly become among the most talked-about medications in modern medicine. For patients considering weight loss injections, the volume of information—and misinformation—can be overwhelming. Here are honest, medically accurate answers to the questions patients ask most frequently.
1. How Do Weight Loss Injections Work?
Semaglutide mimics GLP-1 (glucagon-like peptide-1), a gut hormone released after eating that signals the brain to reduce appetite, slows gastric emptying (so you feel full longer), stimulates insulin secretion in a glucose-dependent manner, and reduces glucagon (a hormone that raises blood sugar). Tirzepatide adds a second mechanism by also mimicking GIP (glucose-dependent insulinotropic polypeptide), which works synergistically with GLP-1 to further improve insulin sensitivity and fat utilization. Together, these mechanisms reduce appetite, improve blood sugar regulation, and shift the body's energy balance toward fat burning.
2. How Much Weight Can I Expect to Lose?
Clinical trial results vary by medication and individual response. The STEP 1 trial of semaglutide 2.4 mg showed average weight loss of approximately 15% of body weight over 68 weeks. The SURMOUNT-1 trial of tirzepatide showed average loss of 20–22% of body weight over 72 weeks. In clinical practice, results vary: some patients lose more, some less. Factors including adherence, diet quality, exercise habits, hormonal health, and genetics all influence outcomes. Weight loss injections are not a substitute for lifestyle change—they are a powerful facilitator of it.
3. Are Weight Loss Injections Safe?
Both semaglutide and tirzepatide have undergone extensive clinical trials involving tens of thousands of participants and have been FDA-approved for weight management. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation—particularly during dose escalation. These symptoms are typically manageable and diminish over time. Serious but rare risks include pancreatitis, gallstone complications, and—in rodent studies only—medullary thyroid carcinoma (not demonstrated in human trials). These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
4. Will I Have to Take Injections Forever?
PCOS, obesity, and weight regulation involve chronic hormonal and metabolic processes—not a temporary condition that is "cured" after weight loss. Studies show that approximately two-thirds of the weight lost on semaglutide is regained within one to two years of stopping the medication, particularly if lifestyle changes have not been made. For many patients, weight loss injections are long-term medications, similar to blood pressure or cholesterol drugs. The goal of an effective weight loss program is to use the medication to create metabolic changes—improved insulin sensitivity, restored hormonal balance, increased muscle mass—that make long-term maintenance more sustainable, whether on or off the medication.
5. Can I Take Weight Loss Injections with Other Medications?
GLP-1 agonists are generally compatible with most medications. The key interaction to be aware of is with insulin and sulfonylureas—the glucose-lowering effect of GLP-1 medications can increase the risk of hypoglycemia in patients on these medications, and dose adjustments are typically needed. There are no significant interactions with most BHRT medications, thyroid medications, blood pressure medications, or statins. Always disclose all medications and supplements to your prescribing physician.
6. How Are the Injections Administered?
Both semaglutide (Wegovy) and tirzepatide (Zepbound) are administered as once-weekly subcutaneous injections—injected into the fatty tissue of the abdomen, thigh, or upper arm. The auto-injector pens are prefilled with a single dose and designed to be self-administered at home. Most patients find the injections straightforward and virtually painless. The needle gauge is very small (typically 32 gauge), and the injection process takes seconds.
7. How Long Before I See Results?
Most patients notice appetite reduction within the first one to two weeks of starting a GLP-1 agonist, even at the starting dose. Measurable weight loss typically begins in the first month and becomes more apparent over three to six months as the dose is gradually increased. The dose escalation schedule—typically starting low and increasing every four weeks—is designed to minimize gastrointestinal side effects. Maximum weight loss is generally reached by 12–18 months on the full maintenance dose.
8. Will I Lose Muscle Mass on Weight Loss Injections?
This is an important concern. Studies have shown that approximately 25–40% of weight lost on GLP-1 medications can come from lean mass (muscle) rather than fat, particularly in patients with low protein intake and minimal resistance training. This muscle loss is metabolically problematic—it reduces resting metabolic rate and can worsen long-term weight management. The mitigation strategy is straightforward: consume adequate protein (1.6–2.2 grams per kilogram of body weight per day) and engage in regular resistance training throughout the weight loss period. These two interventions together dramatically reduce lean mass loss. Optimizing testosterone through BHRT further supports muscle preservation.
9. Is Compounded Semaglutide the Same as Wegovy?
Compounded semaglutide has been widely available during the period when branded Wegovy was on the FDA shortage list. Compounded medications are prepared by licensed compounding pharmacies and are not FDA-approved for safety, efficacy, or quality in the same way branded products are. Quality can vary significantly between compounding pharmacies. The FDA has expressed concern about compounded versions containing semaglutide salts (such as semaglutide acetate or semaglutide sodium) rather than the base form used in Wegovy—these are chemically distinct and have not been proven equivalent. Patients should obtain GLP-1 medications from licensed, reputable sources under physician supervision.
10. How Does Weight Loss Medication Fit with BHRT?
For many patients, weight loss medications and BHRT are complementary and mutually reinforcing. Optimized hormones—particularly testosterone, thyroid, and estrogen—improve insulin sensitivity, support muscle mass, and enhance the body's response to the metabolic benefits of GLP-1 therapy. Conversely, weight loss achieved with GLP-1 medications often improves the hormonal environment: reducing aromatization of testosterone to estrogen in men, improving thyroid conversion, and reducing the inflammatory burden that suppresses hormonal signaling. Integrating both approaches under the care of an experienced physician produces better outcomes than either approach alone.
Explore Your Options with Dr. Bruice
Weight loss injections are powerful tools—but they are most effective when integrated into a comprehensive program that addresses hormones, nutrition, exercise, and metabolic health. Kenton Bruice, M.D., offers medically supervised GLP-1 therapy as part of his comprehensive weight management and BHRT programs at clinics in Denver, Aspen, and St. Louis. Schedule a consultation to find out if weight loss injections are right for you.